Teladoc Health (NYSE:TDOC) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Teladoc Health (NYSE:TDOC) released its quarterly earnings results on Wednesday. The health services provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.07), Zacks reports. The firm had revenue of $640.49 million for the quarter, compared to the consensus estimate of $639.44 million. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. Teladoc Health updated its Q1 2025 guidance to -0.400–0.150 EPS and its FY 2025 guidance to -1.100–0.500 EPS.

Teladoc Health Stock Performance

Shares of TDOC stock traded down $1.26 on Thursday, hitting $9.73. 13,582,969 shares of the stock were exchanged, compared to its average volume of 8,172,402. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $1.68 billion, a PE ratio of -1.69 and a beta of 1.04. Teladoc Health has a one year low of $6.76 and a one year high of $15.95. The firm’s 50 day moving average is $10.61 and its two-hundred day moving average is $9.53.

Insider Transactions at Teladoc Health

In related news, insider Carlos Nueno sold 2,389 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $11.93, for a total transaction of $28,500.77. Following the sale, the insider now owns 2,890 shares of the company’s stock, valued at approximately $34,477.70. This represents a 45.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.95% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. TD Cowen reduced their price target on Teladoc Health from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Thursday, October 31st. Bank of America boosted their price target on Teladoc Health from $11.50 to $13.50 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Barclays boosted their price target on Teladoc Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. Oppenheimer reduced their price target on Teladoc Health from $14.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, January 24th. Finally, Royal Bank of Canada lifted their price objective on Teladoc Health from $11.00 to $12.00 and gave the stock an “outperform” rating in a research note on Friday, January 24th. Eleven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.44.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.